These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8391738)

  • 1. Towards vaccines against human papillomavirus type-16 genital infections.
    Cason J; Khan SA; Best JM
    Vaccine; 1993; 11(6):603-11. PubMed ID: 8391738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer, human papillomavirus and vaccines.
    Khan SA
    Clin Oncol (R Coll Radiol); 1993; 5(6):386-90. PubMed ID: 8305362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection.
    Stanley MA
    Expert Rev Vaccines; 2003 Jun; 2(3):381-9. PubMed ID: 12903803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
    Cornelison TL
    Curr Opin Oncol; 2000 Sep; 12(5):466-73. PubMed ID: 10975555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
    Gérard CM; Baudson N; Kraemer K; Bruck C; Garçon N; Paterson Y; Pan ZK; Pardoll D
    Vaccine; 2001 Mar; 19(17-19):2583-9. PubMed ID: 11257396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccines.
    Stanley MA
    Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response to genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer.
    Gissmann L; Jochmus I; Nindl I; Müller M
    Ann N Y Acad Sci; 1993 Aug; 690():80-5. PubMed ID: 8396380
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
    Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
    Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological response to HPV 16 in cervical dysplasia and neoplasia: correlation of antibodies to E6 with cervical cancer.
    Ghosh AK; Smith NK; Stacey SN; Glew SS; Connor ME; Arrand JR; Stern PL
    Int J Cancer; 1993 Feb; 53(4):591-6. PubMed ID: 8382193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies of human papilloma vaccines in cervical cancer.
    Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Evans AS; Mason M
    Adv Exp Med Biol; 2001; 495():419-27. PubMed ID: 11774604
    [No Abstract]   [Full Text] [Related]  

  • 11. Overview of vaccinology with special reference to papillomavirus vaccines.
    Hilleman MR
    J Clin Virol; 2000 Oct; 19(1-2):79-90. PubMed ID: 11091151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
    Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillomavirus vaccines in clinical trials.
    Galloway DA
    Lancet Infect Dis; 2003 Aug; 3(8):469-75. PubMed ID: 12901889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
    Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
    Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
    Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
    Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of vaccination against HPV infections in cervix carcinoma].
    Gissmann L
    Zentralbl Gynakol; 2001 May; 123(5):299-301. PubMed ID: 11449623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
    Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
    J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R
    Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
    Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
    J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.